Ultraviolet A1 phototherapy decreases inhibitory SMAD7 gene expression in localized scleroderma

Archives of Dermatological Research

Volumn 298, Issue 6, 2006, Pages 265-272

  Kreuter, Alexander ^a   Hyun, Julia ^a   Skrygan, Marina ^a   Sommer, Anna ^a   Tomi, Nordwig S ^a   Breuckmann, Frank ^a   Altmeyer, Peter ^a   Gambichler, Thilo ^a  

^a RUHR UNIVERSITY BOCHUM   (Germany)

Author keywords

Localized scleroderma; Morphea; SMAD3; SMAD4; SMAD7; TGF 1; Ultraviolet irradiation; UVA1

Indexed keywords

MESSENGER RNA; SMAD PROTEIN; SMAD3 PROTEIN; SMAD4 PROTEIN; SMAD7 PROTEIN; TRANSCRIPTION FACTOR; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GENETIC ASSOCIATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LOCALIZED SCLERODERMA; MUTATION; PATHOGENICITY; PHOTOTHERAPY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DETERMINATION; PROTEIN EXPRESSION; RADIATION DOSE; RADIATION INJURY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SKIN DEFECT; STAINING; TREATMENT DURATION; ULTRAVIOLET A RADIATION;

ADULT; AGED; FEMALE; GENE EXPRESSION REGULATION; HUMANS; MIDDLE AGED; RNA, MESSENGER; SCLERODERMA, LOCALIZED; SIGNAL TRANSDUCTION; SKIN; SMAD3 PROTEIN; SMAD4 PROTEIN; SMAD7 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; ULTRAVIOLET RAYS; ULTRAVIOLET THERAPY;

EID: 33749253560     PISSN: 03403696     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00403-006-0695-8     Document Type: Article

References (26)

1. Asano Y, Ihn H, Yamane K, Kubo M, Tamaki K (2004) Impaired SMAD7-Smurf-mediated negative regulation of TGF-β signaling in scleroderma fibroblasts. J Clin Investig 113:253-264
2. Cotton SA, Herrick AL, Jayson MI, Freemont AJ (1998) Endothelial expression of nitric oxide synthases and nitrotyrosine in systemic sclerosis skin. J Pathol 184:4-6
3. Derynck R, Zhang Y, Feng XH (1998) SMADs: transcriptional activators of TGF-β responses. Cell 95:737-740
4. Dong C, Zhu S, Wang T et al (2002) Deficient SMAD7 expression: a putative molecular defect in scleroderma. Proc Natl Acad Sci USA 99:3908-3913
5. Holmes A, Abraham DJ, Sa S, Shiwen X, Black CM, Leask A (2001) CTGF and SMADs, maintenance of scleroderma phenotype is independent of SMAD signaling. J Biol Chem 276:10594-10601
6. Ihn H, Yamane K, Kubo M, Tamaki K (2001) Blockade of endogenous transforming growth factor β signaling prevents up-regulated collagen synthesis in scleroderma fibroblasts: association with increased expression of transforming growth factor β receptors. Arthritis Rheum 44:474-480
7. Ishida W, Mori Y, Lakos G et al (2006) Intracellular tgf-beta receptor blockade abrogates SMAD-dependent fibroblast activation in vitro and in vivo. J Investig Dermatol 126:1733-1744
8. Kawakami T, Ihn H, Xu W, Smith E, LeRoy C, Trojanowska M (1998) Increased expression of TGF-beta receptors by scleroderma fibroblasts: evidence for contribution of autocrine TGF-beta signaling to scleroderma phenotype. J Investig Dermatol 110:47-51
9. Kerscher M, Volkenandt M, Meurer M et al (1994) Treatment of localised scleroderma with PUVA bath photochemotherapy. Lancet 343:1233
10. Kreuter A, Gambicher T, Avermaete A et al (2001) Combined treatment with calcipotriol ointment and low-dose ultraviolet A1 phototherapy in childhood morphea. Pediatr Dermatol 18:241-245
11. Kreuter A, Hyun J, Stücker M, Sommer A, Altmeyer P, Gambichler T (2006) An open randomised controlled study of low-dose UVA1, medium-dose UVA1, and narrow-band UVB phototherapy in the treatment of localized scleroderma. J Am Acad Dermatol 54:440-447
12. Kubo M, Ihn H, Yamane K, Tamaki K (2001) Up-regulated expression of transforming growth factor β receptors in dermal fibroblasts in skin sections of patients with localized scleroderma. Arthritis Rheum 44:731-734
13. LeRoy EC (1992) A brief overview of the pathogenesis of scleroderma (systemic sclerosis). Ann Rheum Dis 51:286-288
14. ΔΔCT method. Methods 25:402-408
15. Massaque J (1998) TGF-β signal transduction. Annu Rev Biochem 67:753-791
16. Mori Y, Chen SJ, Varga J (2003) Expression and regulation of intracellular SMAD signaling in scleroderma skin fibroblasts. Arthritis Rheum 48:1964-1978
17. Peterson LS, Nelson AM, Su WP (1995) Classification of morphea (localized scleroderma). Mayo Clin Proc 70:1068-1076
18. Piek E, Heldin CH, ten Dijke P (1999) Specificity, diversity, and regulation in TGF-β superfamily signaling. FASEB J 13:2105-2124
19. Quan T, He T, Voorhees JJ, Fisher GJ (2001) Ultraviolet irradiation blocks cellular responses to transforming growth factor-β by down-regulating its type-II receptor and inducing SMAD7. J Biol Chem 276:26349-26356
20. Quan T, He TY, Kang S, Voorhees JJ, Fisher GJ (2002) Ultraviolet irradiation alters transforming growth factor β/ SMAD pathway in human skin in vivo. J Investig Dermatol 119:499-506
21. Seyger MMB, van den Hoogen FHJ, de Boo T, de Jong EMGJ (1998) Low-dose methotrexate in the treatment of widespread morphea. J Am Acad Dermatol 39:220-225
22. Stege H, Berneburg M, Humke S et al (1997) High-dose UVA1 radiation therapy for localized scleroderma. J Am Acad Dermatol 36:938-944
23. Takeda K, Hatamochi A, Ueki H, Nakata M, Oishi Y (1994) Decreased collagenase expression in cultured systemic sclerosis fibroblasts. J Investig Dermatol 103:359-363
24. Ten Dijke P, Hansen P, Iwata KK, Pieler C, Foulkes JG (1988) Identification of another member of the transforming growth factor type β gene family. Proc Natl Acad Sci USA 85:4715-4719
25. Varga J (2002) Scleroderma and SMADs. Dysfunctional SMAD family dynamics culminating in fibrosis. Arthritis Rheum 46:1703-1713
26. Yu H, Bock O, Bayat A, Ferguson MW, Morowietz U (2006) Decreased expression of inhibitory SMAD6 and SMAD7 in keloid scarring. J Plast Reconstr Aesthet Surg 59:221-229